

ViroGates' capital raise of DKK 8.2 million and issue of 1,289,510 new shares have been registered

BIRKERØD, DENMARK – ViroGates A/S ("ViroGates" or the "Company"), a medical diagnostics company developing blood tests that can predict disease risk by measuring levels of stable chronic inflammation in individuals, announces that the capital raise of approximately DKK 8.2 million in relation to the directed emission to suPAR Remedy LLC has been completed. The issue of 1,289,510 new shares at a price of DKK 6.34 per share, resulting in a total subscription price of 8,179,224 DKK, has been registered with the Danish Business Authority.

Prior to the increase, the Company's share capital amounted to DKK 6,447,554, consisting of 6,447,554 shares of nominally DKK 1 each. After the nominal increase of DKK 1,289,510, the Company's share capital now amounts to DKK 7,737,064, consisting of 7,737,064 shares of nominally DKK 1 each.

The change in share capital is reflected in the Company's articles of association available on the Company's website.

Further information regarding the directed emission to suPAR Remedy LLC can be found in Company Announcement no. 8 from October 14, 2024.

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: ca@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing blood tests for the measurement of chronic inflammation in health clinics and to improve patient care in hospitals. ViroGates markets its blood test products under the suPARnostic® brand.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates' shares (VIRO) are listed on Nasdag First North Growth Market Denmark. For more information, please visit www.virogates.com.